The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, which are prescribed for both chronic inducible urticaria (CIndU) and chronic spontaneous urticaria (CSU). However, both drug classes have serious side effects, and many patients still struggle to control their lesions. As a result, the approval of Xolair has been welcomed by physicians and patients. Clinical trials for additional biological therapies are underway, capturing urticaria disease data using an array of clinical scoring systems. With only one biological drug currently approved, the most important factors driving prescribing decisions remain unknown, and many of the unmet needs in this market remain unfulfilled.
Geographies: United States, EU5, Japan.
Primary research: 25 country-specific interviews with thought-leading allergists and dermatologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Number of chronic urticaria patients by country, including diagnosed and drug-treated patients
Forecast: 10-year, annualized, drug-level sales and patient share of key chronic urticaria therapies through 2032, segmented by brands/generics.
Emerging therapies: Phase 3 / PR: 2 drugs; Phase 2: 4 drugs
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.